Hologic (NSDQ:HOLX) stock is up in after-hours trading this evening after the company posted fourth-quarter results that met or beat analysts’ expectations.

The Marlborough, Mass.–based women’s health medtech company reported profits of $39.9 million, or 15¢ per share, on sales of $865.8 million for the three months ended Sept. 28, 2019, versus $50.5 million, or 18¢ per share, profits off $813.5 million in sales for the same quarter a year before.

Adjusted to exclude one-time items, earnings per share were 65¢, which matched expectations on The Street, where analysts were looking EPS of 65¢ on sales of $845.73 million.

“We finished fiscal 2019 with our best revenue growth of the year in the fourth quarter,” Hologic CEO Steve MacMillan said in a news release.

“This growth was strong and balanced, with sales increasing in each of our divisions both domestically and outside the United States,” MacMillan said. “In addition to very good results in Breast Health and Molecular Diagnostics, we are excited by the continued strengthening of our Surgical division.”

For the full fiscal year 2019, Hologic lost -$40.2 million, or -15¢ per share, off $2.77 billion in revenue — an improvement over losses of $111.4 million, or -40¢ per share, off $2.64 billion in revenue a year before.

Hologic expects to log an adjusted EPS of $2.60 to $2.65 in fiscal 2020.

Investors initially reacted by sending HOLX shares up more than 2% to $49.60 apiece today in after-hours trading.